The purpose of the study is to evaluate the combination of amifostine and high dose
chemotherapy with blood stem cell support. Amifostine is a druf developed to protect normal
tissues against the toxicities of chemotherapy and radiotherapy and has reduced the side
effects of chemotherapy given at conventional doses.